Many liver transplant recipients with hepatocellular carcinoma are recommended to take sorafenib to prevent recurrence because of the late stage of hepatocellular carcinoma before surgery and the high possibility of metastasis and recurrence after surgery. However, the side effects associated with sorafenib make it difficult for many patients to tolerate and thus discontinue taking the drug or fail to take the full dose. Diarrhea, which has a major impact on the recipient, has a serious impact on quality of life and reduces nutritional absorption and body composition. Diagnosis of Sorafenib-associated diarrhea requires exclusion of infectious diarrhea and other causes of diarrhea. Mycophenolic acid immunosuppressants can also cause diarrhea, and patients can stop taking such drugs first. The mechanism of sorafenib-associated diarrhea is unclear; pancreatic exocrine dysfunction, and its resulting malabsorption of vitamin D, may contribute to the pathogenesis of sorafenib-associated diarrhea and its secondary hypophosphatemia. Slowed intestinal epithelial repair due to sorafenib may also be involved in the development of diarrhea. The pathogenesis and prevention measures are currently under intensive study in our center. Supplementation with pancreatic enzyme preparations can significantly improve diarrhea, and vitamin D supplementation can improve hypophosphatemia. Montmorillonite bulking combined with Lactobacillus bifidum triplex capsules has also shown good results in the treatment of Sorafenib-associated diarrhea. The Chinese patent medicine abdominacoan has also been reported to have some effect. If diarrhea occurs while taking sorafenib, it is recommended to consult your follow-up physician and not to use the drug without authorization.